Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

Preliminary Landmark Findings Presented at the 2021 American Academy of Ophthalmology Conference Show Significantly Reduced Rate of Vision Loss for Glaucoma Patients

IRVINE, Calif., Nov. 15, 2021 /PRNewswire/ -- Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, has announced new data from its five-year HORIZON pivotal trial showing that the Hydrus Microstent lowers the rate of visual field loss by 47% versus cataract surgery alone. The breakthrough findings position the Hydrus Microstent as the first glaucoma procedure to reduce vision loss compared to standard medical treatment in a large randomized clinical trial since trabeculectomy, the gold standard surgical intervention for glaucoma, first did so in the Collaborative Initial Glaucoma Treatment Study over 20 years ago.

The preliminary findings were presented on Saturday, Nov. 13 at 8 a.m. CST during the Original Paper session at the 2021 American Academy of Ophthalmology (AAO) meeting by Dr. Iqbal “Ike” Ahmed, research director at the Kensington Eye Institute and director of the Glaucoma and Advanced Anterior Segment Surgery (GAASS) Fellowship Program at the University of Toronto. The visual field findings are from work done by Dr. Gus Gazzard, professor of ophthalmology at Moorfields Eye Hospital.

“This is a game-changer. Since the inception of MIGS, the impact narrative has been largely restricted to surrogate endpoints – IOP lowering and medication reduction. At three years, we saw that Hydrus was impacting the rate of invasive secondary surgery, which was exciting. Now at five years, we have data indicating the Hydrus is affecting the underlying disease itself, which alters forever how we think of MIGS,” said Dr. Ahmed. “I applaud Dr. Gazzard and commend Ivantis for its tireless commitment and investment in furthering the science of MIGS, without which we would not have these significant outcomes.”

About Visual Field Loss
It is well documented that each decibel reduction in visual field loss from glaucoma has a dramatic impact on patient quality of life and healthcare costs¹. Even a slight loss of vision can create a cascade of medical costs, from added glaucoma medications, surgeries, and doctor visits to additional hospitalizations from fractures and falls, to lost productivity at work.

The new five-year data derive from a review of all visual field follow-ups from baseline through five years for patients in the HORIZON study.

• Involving over 3,000 data points, eyes treated with the Hydrus Microstent show 47% lower rate of Visual Field loss after 5 years².
• The retrospective analysis was led by Professor Gus Gazzard, chief of the glaucoma service at Moorfields Eye Hospital in London, United Kingdom. Full analysis will be presented in its entirety by Dr. Gazzard in early 2022.

“The public health implications of these findings are enormous as a reduction in the rate of visual field progression has the potential to delay or prevent vision loss and blindness in millions of individuals afflicted with glaucoma worldwide,” said Dr. Douglas Rhee, professor and chair of ophthalmology at Case Western Reserve University and University Hospitals and president-elect of the American Society of Cataract and Refractive Surgeons (ASCRS). “Several studies have shown that even small amounts of visual field loss can lead to limitations in common activities such as driving, reading, and a patient’s ability to exercise or go outside the house. Combining Hydrus with cataract surgery is an opportunity to treat patients early in their disease state. With a safe glaucoma surgery like Hydrus, the procedure can be performed in mild or early onset disease before significant visual loss has occurred.”

“In 1925, Dr. J. Stefansson of Winnipeg, Canada published results of his pioneering bypass glaucoma drainage procedure using a T-shaped tube device in the American Journal of Ophthalmology³,” said Dave Van Meter, Ivantis president and CEO. “Nearly 100 years later, his vision has come full circle with the pivotal findings that the Hydrus technology, and its revolutionary, flow enhancing design, reduces vision loss. Overnight, this finding makes MIGS one of the most essential solutions for the globally escalating glaucoma burden and further demonstrates the clinical benefit being provided to patients by Hydrus. It is tremendously gratifying to see the singularly significant impact of Hydrus on glaucoma patients and their quality of life.”

Key Five-Year HORIZON Findings
The HORIZON study is the largest prospective, randomized, controlled trial conducted for a MIGS device and the first with continuous five-year follow-up. HORIZON included 556 patients with mild to moderate glaucoma treated in 38 centers in nine countries in North America, Europe, and Asia. Patients were treated with cataract surgery plus the Hydrus Microstent or cataract surgery alone, respectively. Earlier results showed significant reductions in intraocular pressure (IOP), medication use, and secondary glaucoma surgeries:

• 73% of “mild” Hydrus Microstent patients (those on one glaucoma medication at baseline) remained medication-free at five years, compared with 48% in the cataract surgery-alone arm.
• There was a 20% to 30% improvement in the medication-free rate in the Hydrus group versus control at all time points. This represents the highest margin total of medication eliminations compared to a control group reported for any MIGS pivotal trial.
• With Hydrus, patients had a more than 60% (2.8x) reduction in the likelihood for requiring subsequent invasive glaucoma surgery — a clinically meaningful and statistically significant difference. Hydrus had a 2.5% rate of subsequent invasive glaucoma surgery, compared with 6.4% for cataract surgery alone.
• Confirmed safety at five years, including continued stability of endothelial cell loss compared to control.

About the Hydrus Microstent
Roughly the size of an eyelash, the Hydrus Microstent is a next-generation MIGS device designed to reduce eye pressure by reestablishing flow through Schlemm’s canal, the eye’s natural outflow pathway. When placed in the canal during minimally invasive microsurgery, the device restores the flow of fluid in the eye, using a Tri-Modal® mechanism of action:

1. The Hydrus Microstent dilates and scaffolds Schlemm’s canal to augment outflow of aqueous humor from the anterior chamber.
2. It maintains an opening through the trabecular meshwork from the anterior chamber into Schlemm’s canal.
3. Its length spans approximately 90 degrees of the canal to provide consistent access to multiple fluid collector channels in the eye.

Approved by the FDA in August 2018 for use in conjunction with cataract surgery, the Hydrus Microstent is one of the most rigorously researched and thoroughly studied MIGS devices, with more than 4,000 cases treated globally in controlled clinical studies and registries in patients with a wide range of disease severities.

About Ivantis
Ivantis Inc. is a privately held company established in 2007 to design, develop, and commercialize new technologies to treat eye disease. Investors include New Enterprise Associates, Delphi Ventures, Foresite Capital, RA Capital Management, Ascension Ventures, EDBI, GBS Ventures, MemorialCare Innovation Fund, Merieux Development, and Vertex Healthcare. The company is headquartered in Irvine, California.

Ivantis, Hydrus, and Tri-Modal are registered trademarks of Ivantis Inc. All rights reserved 2021.

References

1. Wang, Yue MD; Alnwisi, Sameh MD; Ke, Min PhD* The impact of mild, moderate, and severe visual field loss in glaucoma on patients’ quality of life measured via the Glaucoma Quality of Life-15 Questionnaire, Medicine: December 2017 - Volume 96 - Issue 48 - p e8019
2. Gazzard et al. AGS 2022 Abstract (in review)
3. Stefansson J. An operation for glaucoma. Am J Ophthalmol 1925;8:681-693.

CAUTION: Federal law restricts this device to sale by or on the order of a physician.

INDICATIONS FOR USE:
The Hydrus Microstent is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma (POAG).

CONTRAINDICATIONS:
The Hydrus Microstent is contraindicated under the following circumstances or conditions: (1) In eyes with angle-closure glaucoma; and (2) In eyes with traumatic, malignant, uveitic or neovascular glaucoma, or discernible congenital anomalies of the anterior chamber (AC) angle.

WARNINGS
Clear media for adequate visualization is required. Conditions such as corneal haze, corneal opacity, or other conditions may inhibit gonioscopic view of the intended implant location. Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, peripheral anterior synechiae (PAS), angle closure, rubeosis, and any other angle abnormalities that could lead to improper placement of the stent and pose a hazard.

PRECAUTIONS
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure. The safety and effectiveness of the Hydrus Microstent has not been established as an alternative to the primary treatment of glaucoma with medications in patients 21 years or younger, eyes with significant prior trauma, eyes with abnormal anterior segment, eyes with chronic inflammation, eyes with glaucoma associated with vascular disorders, eyes with preexisting pseudophakia, eyes with uveitic glaucoma, eyes with pseudoexfoliative or pigmentary glaucoma, eyes with other secondary open-angle glaucomas, eyes that have undergone prior incisional glaucoma surgery or cilioablative procedures, eyes that have undergone argon laser trabeculoplasty (ALT), eyes with unmedicated IOP < 22 mmHg or > 34 mmHg, eyes with medicated IOP > 31 mmHg, eyes requiring > 4 ocular hypotensive medications prior to surgery, in the setting of complicated cataract surgery with iatrogenic injury to the anterior or posterior segment, and when implantation is without concomitant cataract surgery with IOL implantation. The safety and effectiveness of the use of more than a single Hydrus Microstent has not been established.

ADVERSE EVENTS
Common postoperative adverse events reported in the randomized pivotal trial included partial or complete device obstruction (7.3%); worsening in visual field MD by > 2.5 dB compared with preoperative (4.3% vs. 5.3% for cataract surgery alone); device malposition (1.4%); and BCVA loss of ≥ 2 ETDRS lines ≥ three months (1.4% vs. 1.6% for cataract surgery alone). For additional adverse event information, please refer to the Instructions for Use.

MRI INFORMATION
The Hydrus Microstent is MR-Conditional, meaning that the device is safe for use in a specified MR environment under specified conditions; please see the Instructions for Use and Patient Information Card for details.

Please refer to the Instructions for Use for complete product information.

www.IvantisInc.com

Media Contact
Capwell Communications
info@capwellcomm.com
949-999-3303

View original content to download multimedia:https://www.prnewswire.com/news-releases/hydrus-microstent-lowers-visual-field-loss-by-47-according-to-new-5-year-pivotal-trial-data-301423785.html

SOURCE Ivantis, Inc.